• Strong financial performance with double digit revenue and underlying profit growth (at CER).
  • Good progress made on delivering our global growth strategy.
  • EU Pharmaceuticals revenue grew by 3.9% (at CER) with a strong performance in Companion Animal Products (CAP) partly offset by a decline in Food producing Animal Products (FAP).
  • Excellent performance in North America Pharmaceuticals with a revenue increase of 59.9% (at CER), driven by the growth of our core brands, new product launches and the acquired product, Phycox®.
  • Continued geographical expansion with trading commencing in two new subsidiaries in Canada and Poland.
  • Advances in the short term pipeline with approval of TAF Spray® and Osphos® in EU, and filing of Zycortal®.
  • Investment made in sales resources, infrastructure and manufacturing to support our future growth.
  • Conditional offer of €51.4 million made for Genera d.d. announced on 3 August 2015 to enable us to enter the poultry vaccines market.
  • Cash conversion of 107.1% and a net cash position of £13.4 million.